1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Nasopharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Nasopharyngeal Squamous Cell Carcinoma trials Research Report on Recurrent Nasopharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial Toripalimab - Nasopharyngeal Carcinoma, Toripalimab | Phase 2 | Unknown | Cancer Hospital of Guangxi Medical University | 40 | 2020-06-28 | 2021-08-20 |
Nasopharyngeal Carcinoma (3) · Carcinoma (2) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Mouth Neoplasms (2) · Oropharyngeal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Lymphoid Interstitial Pneumonia (1)
Head and Neck Neoplasms (3) · Nasopharyngeal Diseases (3) · Nasopharyngeal Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Pharyngeal Diseases (3) · Pharyngeal Neoplasms (3) · Stomatognathic Diseases (3) · Carcinoma, Squamous Cell (2) · Laryngeal Diseases (2) · Mouth Diseases (2)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · (225)Ac-DOTA-c(RGDyK) (1) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Disulfides (1) · Docetaxel (1) · Immunoglobulin G (1) · Lovastatin (1) · Platinum (1) · atezolizumab (1) · pembrolizumab (1)
Cancer Hospital of Guangxi Medical University (1) · Emory University (1) · National Cancer Institute (NCI) (1)
United States (2) · China (1)
Aarti Bhatia (1) · Nicole C Schmitt, D, FACS (1)
PMID 11224527, PMID 16382236, PMID 18173375, PMID 30207593
P30CA138292 (1), U10CA180820 (1)